The current analysis involved the participants with both obesity and prediabetes, who received their assigned dose of tirzepatide or placebo for a total of 176 weeks, followed by a 17-week off ...

Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...

Tirzepatide demonstrated sustained average weight loss of 22.9% (15 mg dose) through the three-year treatment period. The study showed an association of tirzepatide treatment with improved ...

Tirzepatide, administered weekly via injection, significantly ‘decreased’ the risk of developing T2D compared to placebo over 176 weeks. At the highest 15mg dose, participants showed sustained ...

Results showed that tirzepatide reduced the risk of developing Type 2 diabetes by 94% compared to the placebo, with an average body weight reduction of up to 23% with the highest dose, according ...

In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking tirzepatide for up to 3 years had a reduced combined risk of worsening heart failure ...

As reported in August, the highest dose of tirzepatide tested—15 mg—also helped patients lose an average of 22.9% of their body weight, versus just 2.1% in the trial’s control arm.

Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and obese ...

Findings at week 176 demonstrated that among prediabetic patients treated with tirzepatide (efficacy estimand; pooled doses of 5mg, 10mg, 15mg), 98.8% remained diabetes free. Detailed results were ...

At the 15mg dose, participants showed a sustained average weight loss of 22.9% during the three-year treatment. Credit: SB Arts Media / Shutterstock. Eli Lilly has reported comprehensive outcomes from ...